RNA interference
RNA Interference Drug Excels in Clinical Trials to Treat Rare Disorder
RNA Interference Drug Excels in Clinical Trials to Treat Rare Disorder
Katarina Zimmer | Nov 3, 2017
If approved, patisiran will be the first RNAi therapeutic on the market. 
CRISPR System Targets RNA in Mammalian Cells
CRISPR System Targets RNA in Mammalian Cells
Anna Azvolinsky | Oct 4, 2017
Researchers engineer bacterial CRISPR-Cas13 to knock down RNA in mammalian cells.
Vitamin C Blocks Leukemia Progression in Mice
Vitamin C Blocks Leukemia Progression in Mice
Aggie Mika | Aug 17, 2017
High-dose vitamin C injections reverse the effects of a leukemia-promoting genetic deficiency.
RNAi’s Future in Drug-Target Screening
RNAi’s Future in Drug-Target Screening
Catherine Offord | Apr 17, 2017
A recent CRISPR study contradicted years of RNA interference research on a well-studied cancer drug target. But is it the last nail in the coffin for RNAi as a screening tool? 
A Walk on the Wild Side
A Walk on the Wild Side
Mary Beth Aberlin | Feb 1, 2017
Plants have so much to teach us.
RNA Interference Between Kingdoms
RNA Interference Between Kingdoms
Kerry Grens | Feb 1, 2017
Plants and fungi can use conserved RNA interference machinery to regulate each other’s gene expression—and scientists think they can make use of this phenomenon to create a new generation of pesticides.
Oligonucleotide Therapeutics Near Approval
Oligonucleotide Therapeutics Near Approval
Catherine Offord | Dec 1, 2016
Successful late-stage clinical trials could mark the maturation of a new drug development platform, but the path to commercialization is not without hurdles.
Gut Bacteria for Insect RNAi
Gut Bacteria for Insect RNAi
Ruth Williams | Jun 1, 2016
Lacing insect food with microbes encoding double-stranded RNAs can suppress insect gene expression.
Metazoans in the DNAi Club
Metazoans in the DNAi Club
Amanda B. Keener | Jul 1, 2015
A chance discovery results in the first report of DNA-based gene silencing in an animal.
Ebola Drug Trial Terminated
Ebola Drug Trial Terminated
Amanda B. Keener | Jun 23, 2015
Early analysis of TKM-Ebola-Guinea offers discouraging results, causing sponsors to end the Phase 2 trial.